- Home
- DM vs IMUX Comparison
DM vs IMUX Comparison
Compare DM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DM
- IMUX
- Stock Information
- Founded
- DM 2015
- IMUX 2016
- Country
- DM United States
- IMUX United States
- Employees
- DM N/A
- IMUX N/A
- Industry
- DM Industrial Machinery/Components
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- DM Technology
- IMUX Health Care
- Exchange
- DM Nasdaq
- IMUX Nasdaq
- Market Cap
- DM 87.7M
- IMUX 102.2M
- IPO Year
- DM N/A
- IMUX N/A
- Fundamental
- Price
- DM $4.93
- IMUX $1.12
- Analyst Decision
- DM Hold
- IMUX Strong Buy
- Analyst Count
- DM 1
- IMUX 7
- Target Price
- DM $5.50
- IMUX $12.67
- AVG Volume (30 Days)
- DM 3.4M
- IMUX 572.2K
- Earning Date
- DM 05-08-2025
- IMUX 05-07-2025
- Dividend Yield
- DM N/A
- IMUX N/A
- EPS Growth
- DM N/A
- IMUX N/A
- EPS
- DM N/A
- IMUX N/A
- Revenue
- DM $168,283,000.00
- IMUX N/A
- Revenue This Year
- DM N/A
- IMUX N/A
- Revenue Next Year
- DM $6.25
- IMUX N/A
- P/E Ratio
- DM N/A
- IMUX N/A
- Revenue Growth
- DM N/A
- IMUX N/A
- 52 Week Low
- DM $1.84
- IMUX $0.92
- 52 Week High
- DM $11.80
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- DM 81.39
- IMUX 55.66
- Support Level
- DM $2.18
- IMUX $1.18
- Resistance Level
- DM $2.79
- IMUX $1.35
- Average True Range (ATR)
- DM 0.29
- IMUX 0.06
- MACD
- DM 0.32
- IMUX 0.00
- Stochastic Oscillator
- DM 96.93
- IMUX 48.28
About DM Desktop Metal Inc.
Desktop Metal Inc manufactures 3D printing to make metal and carbon fiber 3D printing accessible to all engineers, designers, and manufacturers. 3D metal printing helps in the design and development of automotive parts, consumer goods, manufacture of industrial equipment, and design of mechanical systems. The company ships its product to markets in the Americas, Europe Middle East and Africa (EMEA), and Asia Pacific (APAC). It derives maximum revenue from Americas.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.